Trials / Completed
CompletedNCT06530966
Phase I Study of ICP-332 in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- InnoCare Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-332 Tablets | Eligible patients will receive ICP-332 tablets orally as per the protocol |
| DRUG | ICP-332 Placebo Tablets | Eligible patients will receive ICP-332 placebo tablets orally as per the protocol |
Timeline
- Start date
- 2024-07-23
- Primary completion
- 2024-11-08
- Completion
- 2024-11-08
- First posted
- 2024-07-31
- Last updated
- 2026-04-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06530966. Inclusion in this directory is not an endorsement.